Sleep Apnea Symptoms: When to See a Doctor

What Sleep Apnea Actually Looks Like

Sleep apnea is not just snoring. The condition involves repeated partial or complete collapse of the upper airway during sleep, causing oxygen desaturation, fragmented sleep architecture, and systemic stress responses that compound over months and years. Recognizing the full symptom picture is the first step toward getting tested.

The hallmark presentation includes three features: habitual loud snoring, breathing pauses observed by a bed partner, and excessive daytime sleepiness (EDS). But the symptom profile extends well beyond this triad. Patients frequently report morning headaches, dry mouth on waking, nocturia (waking two or more times per night to urinate), difficulty concentrating, and irritability 1.

Women often present differently from men. A 2013 analysis from the Wisconsin Sleep Cohort found that women with OSA were more likely to report insomnia, mood disturbance, and fatigue rather than classic loud snoring 2. This difference in presentation contributes to underdiagnosis. The same study estimated that 23.4% of women and 49.7% of men aged 30 to 70 have at least mild OSA (AHI ≥ 5).

Not every snorer has sleep apnea. The distinguishing feature is witnessed cessation of breathing. If someone watches you sleep and sees pauses lasting 10 seconds or longer followed by a gasping or choking recovery breath, that pattern strongly suggests obstructive sleep apnea 3.

Red-Flag Symptoms That Demand Prompt Evaluation

Schedule an appointment with your primary care physician or a sleep medicine specialist if you experience any combination of witnessed apneas, daytime sleepiness severe enough to impair driving or occupational performance, or treatment-resistant hypertension. These three findings carry the strongest clinical weight for referral.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline recommends diagnostic testing for adults who present with "unresolved excessive sleepiness, or signs and symptoms suggestive of obstructive sleep apnea" 1. That recommendation applies even when patients do not report snoring, because 10 to 15% of confirmed OSA patients deny habitual snoring altogether.

Certain populations face higher urgency. Patients with atrial fibrillation, heart failure (NYHA class II or higher), stroke, or type 2 diabetes should be screened proactively. A Lancet study by Marin et al. (2005) followed 1,651 men for a median of 10.1 years and found that those with severe untreated OSA (AHI >30) had a 3.8-fold increase in fatal cardiovascular events and a 3.2-fold increase in nonfatal events compared to healthy controls 4.

Do not wait for the "classic" picture. Persistent morning headaches, unrefreshing sleep for three or more months, or a bed partner who moves to another room because of your snoring are all reasons to bring the topic up with your doctor.

What Causes Sleep Apnea

Obstructive sleep apnea results from anatomical and neuromuscular factors that allow the pharyngeal airway to collapse during sleep. Obesity is the single strongest modifiable risk factor, with a body mass index above 30 roughly doubling the odds of moderate-to-severe OSA compared to normal weight 5.

Craniofacial anatomy plays a significant role independent of weight. A retrognathic mandible (recessed jaw), enlarged tonsils, a large tongue base, and a low-lying soft palate all narrow the pharyngeal space. These features explain why some lean patients, including athletes and young adults, develop clinically significant OSA 6.

Other contributors include nasal obstruction (deviated septum, chronic rhinitis), alcohol use within three hours of bedtime (which relaxes pharyngeal dilator muscles), sedative medications including benzodiazepines and opioids, smoking, and supine sleep position. Age-related loss of pharyngeal muscle tone explains the rising prevalence after age 40 5.

Central sleep apnea (CSA), a less common variant, involves failure of the brainstem respiratory drive rather than airway collapse. CSA is associated with heart failure, opioid use, and high-altitude exposure. Mixed or "complex" sleep apnea, where central events emerge after CPAP eliminates obstructive events, occurs in roughly 5 to 15% of patients initiated on positive airway pressure therapy 7.

Dr. Atul Malhotra, a pulmonary and sleep medicine physician at UC San Diego, has stated: "Obesity is by far the dominant risk factor, but we see plenty of normal-weight patients whose anatomy puts them at risk. Screening should not be limited to patients who fit the stereotypical profile" 6.

How Sleep Apnea Is Diagnosed

The gold standard for diagnosing sleep apnea is overnight polysomnography (PSG) conducted in a sleep laboratory, though home sleep apnea testing (HSAT) is now an accepted alternative for uncomplicated adult cases. Your doctor will choose the test based on your pre-test probability, comorbidities, and insurance coverage.

The AASM recommends HSAT for patients with a high pre-test probability of moderate-to-severe OSA who do not have significant cardiopulmonary disease, suspected central sleep apnea, or other sleep disorders such as periodic limb movement disorder 1. HSAT devices measure airflow, respiratory effort, and oxygen saturation. They cost less and allow the patient to sleep at home, but they tend to underestimate disease severity because they use recording time rather than actual sleep time as the denominator.

In-lab PSG records electroencephalography (EEG), electromyography (EMG), electrooculography (EOG), airflow, respiratory effort, oxygen saturation, body position, and cardiac rhythm. This comprehensive picture allows scoring of the apnea-hypopnea index (AHI), which counts the average number of apneas (complete airflow cessation for ≥10 seconds) and hypopneas (partial airflow reduction with ≥3% oxygen desaturation or arousal) per hour of sleep 8.

OSA severity classification by AHI:

• Mild: 5 to 14 events per hour
• Moderate: 15 to 29 events per hour
• Severe: 30 or more events per hour

A negative HSAT does not rule out sleep apnea. The AASM guideline specifies that if clinical suspicion persists after a negative or technically inadequate home test, in-laboratory PSG should follow 1.

The Epworth Sleepiness Scale (ESS), a validated eight-question self-report tool, quantifies daytime sleepiness. Scores above 10 (out of 24) indicate excessive sleepiness and support referral for diagnostic testing 9.

Treatment Options for Sleep Apnea

CPAP remains the first-line therapy for moderate-to-severe obstructive sleep apnea, reducing AHI to below 5 events per hour in most patients when used consistently. Treatment choice depends on severity, patient anatomy, tolerance, and preferences.

Continuous positive airway pressure (CPAP). A CPAP machine delivers a fixed pressure through a nasal or oronasal mask to pneumatically splint the airway open during sleep. A meta-analysis published in JAMA (2015) found that CPAP reduced the AHI by a mean of 33.8 events per hour and improved Epworth Sleepiness Scale scores by 2.5 points compared to sham CPAP 10. Adherence is the primary challenge. Medicare defines adequate use as ≥4 hours per night on ≥70% of nights, but clinical benefit increases with longer nightly use.

Oral appliances. Mandibular advancement devices (MADs) hold the lower jaw forward during sleep, enlarging the retropalatal and retroglossal airway. The AASM and American Academy of Dental Sleep Medicine recommend MADs for mild-to-moderate OSA, or for patients with severe OSA who cannot tolerate CPAP 11. Custom-fitted devices outperform over-the-counter versions.

Weight loss. The Sleep AHEAD study found that intensive lifestyle intervention producing 10.2 kg of weight loss over one year yielded a 9.7-event-per-hour reduction in AHI 12. GLP-1 receptor agonists, including tirzepatide, are now under investigation for OSA. The SURMOUNT-OSA trial (N=469) demonstrated that tirzepatide reduced AHI by up to 62.8% at 52 weeks compared to 6.4% with placebo, along with a 20.1% mean body weight reduction 13.

Positional therapy. For patients whose AHI is at least twice as high in the supine position, positional devices that encourage lateral sleep can be effective adjuncts.

Surgery. Uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), and hypoglossal nerve stimulation (Inspire device) are reserved for patients who fail or refuse positive airway pressure. The STAR trial demonstrated that hypoglossal nerve stimulation reduced the median AHI from 29.3 to 9.0 events per hour at 12 months in patients with moderate-to-severe OSA who could not tolerate CPAP 14.

Dr. Sanjay Patel, director of the Center for Sleep and Cardiovascular Outcomes Research at the University of Pittsburgh, has noted: "We now have multiple effective treatments beyond CPAP. The key is matching the right therapy to the right patient rather than treating sleep apnea as a one-size-fits-all condition" 6.

The Cardiovascular Stakes of Ignoring Symptoms

Untreated obstructive sleep apnea does not simply cause tiredness. It raises blood pressure, promotes systemic inflammation, increases sympathetic nervous system activity, and accelerates atherosclerosis. These downstream effects explain why OSA is now recognized as an independent cardiovascular risk factor by the American Heart Association.

The mechanisms are well characterized. Each apnea episode triggers intermittent hypoxia (oxygen desaturation) and re-oxygenation, producing oxidative stress and endothelial dysfunction 15. Intrathoracic pressure swings during obstructed breathing increase left ventricular afterload. Arousals from sleep drive surges in catecholamines that raise heart rate and blood pressure.

Prospective data quantify the risk. In the Marin et al. cohort, men with untreated severe OSA (AHI >30) had a cardiovascular event rate of 2.87 per 100 person-years, compared to 0.55 in healthy controls 4. Resistant hypertension (blood pressure uncontrolled on three or more medications) is present in 70 to 83% of patients referred to sleep clinics, and OSA is the most common secondary cause 15.

The SAVE trial (N=2,717), published in the New England Journal of Medicine in 2016, randomized patients with moderate-to-severe OSA and established cardiovascular disease to CPAP plus usual care versus usual care alone. CPAP did not reduce major adverse cardiovascular events over 3.7 years of follow-up, but average nightly CPAP use was only 3.3 hours, below the threshold where cardiovascular benefits have been observed in observational studies 16. Subgroup analysis showed that patients using CPAP for more than 4 hours per night had lower event rates, reinforcing the dose-response relationship between adherence and benefit.

Sleep Apnea in Special Populations

Certain groups face distinct patterns of risk, presentation, and treatment response. A single diagnostic and treatment algorithm does not fit everyone.

Women. OSA prevalence in women rises sharply after menopause, likely related to declining progesterone (a respiratory stimulant) and redistributing body fat toward the upper airway. Pre-menopausal women with OSA more often present with insomnia, fatigue, and depression rather than snoring and witnessed apneas 2. This atypical presentation delays diagnosis by an average of several years compared to men.

Older adults. AHI increases with age, but the clinical significance of mild elevations in older adults is debated. The AASM recommends treating symptomatic patients regardless of age. Cognitive decline, nocturia, and falls risk are outcomes of particular concern in patients over 65 with untreated OSA 1.

Children. Pediatric OSA affects 1 to 5% of children, most commonly due to adenotonsillar hypertrophy. The American Academy of Pediatrics recommends polysomnography for children who snore regularly and exhibit behavioral problems, poor school performance, or enuresis. Adenotonsillectomy is the first-line treatment; CPAP is reserved for residual disease or children who are not surgical candidates 17.

Patients on opioid therapy. Chronic opioid use increases the risk of central and mixed sleep apnea. Patients on long-term opioid therapy (≥30 morphine milligram equivalents per day) should be screened with polysomnography rather than HSAT, because home tests do not reliably detect central events 1.

Screening Tools You Can Use Before Your Appointment

Before visiting your doctor, you can use validated questionnaires to gauge your risk and better articulate your symptoms during the visit. These tools do not replace a sleep study but help prioritize who needs testing.

The STOP-Bang questionnaire scores eight yes-or-no items: Snoring, Tiredness, Observed apneas, blood Pressure, BMI >35, Age >50, Neck circumference >40 cm, and male Gender. A score of 5 to 8 indicates high probability of moderate-to-severe OSA, with a sensitivity of 93% for AHI ≥15 18.

The Epworth Sleepiness Scale asks you to rate your likelihood of dozing in eight everyday situations (watching television, sitting in traffic, reading). A total score above 10 suggests clinically significant daytime sleepiness 9.

Keep a two-week sleep diary noting bedtime, wake time, number of awakenings, and how refreshed you feel each morning. Ask your bed partner to observe and record snoring intensity and any pauses in breathing. Bring this information to your appointment.

If your STOP-Bang score is 3 or higher, request a sleep evaluation rather than waiting for symptoms to worsen. Early diagnosis and treatment reduce daytime accident risk, lower blood pressure by 2 to 3 mmHg on average with consistent CPAP use, and improve quality of life scores 10.